Claims for Patent: 8,394,377

Summary for Patent: 8,394,377

Title:	Methods for treating cancer using combination therapy
Abstract:	The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof.
Inventor(s):	Newell; Martha Karen (Holland, TX), Cabrera; Joshua Hunter (Colorado Springs, CO)
Assignee:	The Regents of the University of Colorado (Denver, CO)
Application Number:	12/918,741
Patent Claims:	1. A method of treating breast cancer, comprising: administering to a subject having breast cancer an effective amount of etomoxir and an anti-human epidermal growth factor receptor 2 (HER-2) antibody to treat the breast cancer, wherein the antibody is trastuzumab further comprising identifying the subject as a subject that has a HER-2 lo/ negative cancer. 2. The method of claim 1, further comprising administering a fatty acid oxidation inhibitor comprising at least one of cerulenin, 5-(tetradecyloxy)-2-firoic acid, oxfenicine, methyl palmoxirate, metoprolol, amiodarone, perhexiline, aminocarnitine, hydrazonopropionic acid, 4-bromocrotonic acid, trimetazidine, ranolazine, hypoglycin, dichloroacetate, methylene cyclopropyl acetic acid, or beta-hydroxy butyrate. 3. The method of claim 1, wherein the cancer is a HER-2 lo/negative cancer. 4. The method of claim 1, further comprising administering a chemotherapeutic agent to the subject. 5. The method of claim 1, further comprising administering a glycolytic inhibitor to the subject. 6. The method of claim 1, wherein the anti-HER-2 antibody is a humanized monoclonal antibody. 7. A method of treating cancer comprising: administering to a subject having a HER-2 lo/negative cancer an effective amount of etomoxir to induce expression of HER-2 on a cancer cell and an anti-HER-2 antibody, wherein the antibody is trastuzumab and wherein the cancer is a breast cancer and wherein the cancer is resistance to chemotherapy. 8. The method of claim 7, further comprising administering a fatty acid oxidation inhibitor comprising at least one of cerulenin, 5-(tetradecyloxy)-2-furoic acid, oxfenicine, methyl palmoxirate, metoprolol, amiodarone, perhexiline, aminocarnitine, hydrazonopropionic acid, 4-bromocrotonic acid, trimetazidine, ranolazine, hypoglycin, dichloroacetate, methylene cyclopropyl acetic acid, or beta-hydroxy butyrate. 9. The method of claim 7, further comprising administering a chemotherapeutic agent to the subject. 10. The method of claim 7, further comprising administering a glycolytic inhibitor to the subject. 11. The method of claim 7, wherein the anti-HER-2 antibody is a humanized monoclonal antibody. 12. A method, comprising: identifying a subject having a HER-2 lo/negative cancer, wherein the cancer is a breast cancer, and administering to the subject an effective amount of etomoxir to induce expression of HER-2 on a breast cancer cell. 13. A method for inducing expression of HER-2 on a breast cancer cell, comprising contacting the breast cancer cell with an effective amount of a etomoxir to induce expression of HER-2 on the breast cancer cell.

Details for Patent 8,394,377

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-02-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-02-21
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2028-02-21